(Q48139886)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Stefano Fanti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Paolo Castellucci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Tiziano Graziani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Riccardo Schiavina

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Riccardo Renzi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Marco Borghesi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Piergiorgio Di Tullio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Eugenio Brunocilla

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Andrea Ardizzoni

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

number of pages

8

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

84-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Castration-resistant prostate cancer: from new pathophysiology to new treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

[11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3177-4

Prostate cancer, version 2.2014

21 January 2018

1 reference

12 December 2020

11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients

1 reference

12 December 2020

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

1 reference

12 December 2020

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

12 December 2020

10.1007/S00259-015-3177-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26323576%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference